Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer ; volume:17 ; number:3 ; day:5 ; month:5 ; year:2022 ; pages:381 ; date:5.2022
Targeted oncology ; 17, Heft 3 (5.5.2022), 381, 5.2022
- Creator
-
Scott, Lesley J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-022-00885-y
- URN
-
urn:nbn:de:101:1-2022081423181431302516
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scott, Lesley J.
- SpringerLink (Online service)
Other Objects (12)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management